Study of Extracorporeal Carbon Dioxide Removal Using PrismaLung to Lower Lung Injury in Adults with ARDS on Mechanical Ventilation

What this Trial Is About

Researchers are evaluating the use of a device called PrismaLung for extracorporeal carbon dioxide removal ECCO2R in adults with acute respiratory distress syndrome ARDS who are mechanically ventilated. The study focuses on how this device may help reduce ventilator-induced lung injury by lowering harmful pressures and inflammation in the lungs. This observational study is sponsored by Peninsula Health and aims to better understand how managing carbon dioxide levels can impact lung injury and patient outcomes. Participants will receive low flow extracorporeal carbon dioxide removal using the PrismaLung device while receiving lung protective ventilation. The study measures include monitoring airway pressures at 72 and 144 hours after starting ECCO2R. Researchers also assess lung inflammation by measuring interleukin levels in bronchoalveolar lavage fluid and blood to evaluate the impact of treatment on lung injury. During the study, adult patients diagnosed with ARDS will be closely monitored with clinical assessments, laboratory tests, and pressure measurements. The main outcome is the reduction in driving airway pressure, while secondary outcomes include decreased pulmonary inflammation. The study excludes patients with ARDS lasting more than 72 hours or other severe conditions. Participation involves continuous monitoring over several days to understand the effects of the PrismaLung device on lung injury and respiratory function.

Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury